PATENT CLAIM ANALYSIS

Application Number: 15564531
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-05
Patent Classification: ["514", "629000"]

Abstract:
The present invention relates to methods and compositions for treating heart failure in a subject using histone deacetylase (HDAC) inhibitors and/or histone acetyltransferases (HAT) activators.

Claim (Index 28):
The method of  claim 1 , wherein the HDAC inhibitor is a short-chain fatty acid, a hydroxamic acid, a cyclic tetrapeptide, a benzamide, a tricyclic lactam, a sultam derivative, an organosulfur compound; a electrophilic ketone, pimeloylanilide o-aminoanilide (PAOA), depudecin, a psammaplin, Vorinostat, tubacin, curcumin, histacin, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-l-carboxamide, CRA-024781, CRA-026440, CG1521, PXD101, G2M-777, CAY10398, CTPB MGCDO103, CUDC-100, and/or any derivative thereof or combination thereof.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 88.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11365268', '14777211', '14884827', '14650473', '12851610']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7417900645216275
- 35 USC 102 Novelty (BERT): 0.5307371989613208
- Combined Prediction Score: 0.7206847779655969
- Mean Citation Score: 264.59926
- Max Citation Score: 313.5870700000001
- Similarity Product: 203.59224661957927

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test